Central nervous system analgesics
AfaSci has developed small molecule New Chemical Entities (NCEs) that differentially inhibit ion channels and exhibit state-dependent modulation of neuronal activity. The lead compounds are highly potent and selective, and produce in vivo efficacy against epilepsy and nerve injury-induced neuropathic pain, diabetes- or chemotherapy-induced peripheral neuropathy in rodents.
Status: Phase I first-in-human trials succesfully completed in Q4 2024.